Harvard Health Letter

The shingles vaccine: Why hasn't it caught on?

The shingles vaccine Zostavax has not turned out to be as popular as was expected, due in part to its high cost and questions about its effectiveness.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In